{'fraction_non_alphanumeric': 0.030660377358490566, 'fraction_numerical': 0.04363207547169811, 'mean_word_length': 4.815068493150685, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Experience with ceftazidime in obstetrics and gynaecology in Japan.

The effects of ceftazidime were evaluated in 238 patients. Among these patients 221 (93%) were assessed as having either 'excellent' or 'good' clinical responses. Bacteriologically, in 102 (87%) out of 117 cases, the causative organisms were either eliminated or replaced. Adverse events noted were limited to mild rashes in 2 patients and gastric discomfort in another. Penetration of ceftazidime into uterine tissues was studied and, following an intravenous bolus dose of 1 g, concentrations in various parts of the uterus averaged 36 to 57 mg/kg at 11 to 26 min. Concentrations in intrapelvic fluid in patients undergoing radical hysterectomy averaged 37 mg/l at 30 min after an intravenous bolus injection of 1 g, and 23 mg/l at 30 min after completion of a 60-min infusion.